TAFINLAR Drug Patent Profile

When do Tafinlar patents expire, and what generic alternatives are available?

Tafinlar is a drug marketed by Novartis and is included in two NDAs. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-seven patent family members in forty-two countries.

The generic ingredient in TAFINLAR is dabrafenib mesylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the dabrafenib mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Tafinlar

Tafinlar was eligible for patent challenges on May 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 16, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TAFINLAR

International Patents:	137
US Patents:	7
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TAFINLAR

Paragraph IV (Patent) Challenges for TAFINLAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAFINLAR	Capsules	dabrafenib mesylate	50 mg and 75 mg	202806	1	2025-11-13

US Patents and Regulatory Information for TAFINLAR

TAFINLAR is protected by seven US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No	7,994,185*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes	7,994,185*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No	8,952,018*PED				Y

International Patents for TAFINLAR

When does loss-of-exclusivity occur for TAFINLAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Russian Federation

Serbia

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAFINLAR around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20080018
Eurasian Patent Organization	201001680
Chile	2012000964
Norway	2016021
Poland	2298768
Australia	2005252110	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer

Supplementary Protection Certificates for TAFINLAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761528	205 5032-2014	Slovakia		PRODUCT NAME: TRAMETINIB, PRIPADNE VO FORME JEHO FARMACEUTICKY PRIJATELNEJ SOLI, HYDRATU ALEBO SOLVATU; REGISTRATION NO/DATE: EU/1/14/931 20140702
1761528	68/2014	Austria		PRODUCT NAME: TRAMETINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES, HYDRATS ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/14/931 (MITTEILUNG) 20140702
1761528	122014000102	Germany		PRODUCT NAME: TRAMETINIB, GEGEBENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES, HYDRATS ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140630
1761528	SPC/GB14/081	United Kingdom		PRODUCT NAME: TRAMETINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACEPTABLE SALT, HYDRATE OR SOLVATE THEREOF.; REGISTERED: UK EU/1/14/931(01-06) 20140702
1761528	CR 2014 00055	Denmark		PRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140702
1761528	C300701	Netherlands		PRODUCT NAME: TRAMETINIB, DESGEWENST IN DE VORM VAN EEN FRAMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140702

TAFINLAR (Dabrafenib) Investment Analysis: Patent Landscape and Market Position

Last updated: February 19, 2026

TAFINLAR (dabrafenib) is a targeted therapy drug developed by Novartis, indicated for the treatment of certain cancers, primarily BRAF V600 mutation-positive melanoma and non-small cell lung cancer (NSCLC). Its efficacy is linked to the inhibition of mutated BRAF kinases, a common driver in these malignancies. The investment landscape for TAFINLAR is shaped by its patent protection, clinical utility, and the competitive environment.

What is the Current Patent Status of TAFINLAR?

The primary patent protecting TAFINLAR is U.S. Patent No. 8,048,887, titled "PYRIDINE AND PYRAZINE DERIVATIVES AS RAF KINASE INHIBITORS." This patent was filed on January 15, 2008, and granted on November 1, 2011. It has a statutory expiration date of January 15, 2028, without accounting for any potential patent term extensions (PTEs) or adjustments.

Novartis has also secured additional patents covering various aspects of dabrafenib, including:

• Formulations: Patents protecting specific salt forms or solid-state forms of dabrafenib, which can extend market exclusivity.
• Methods of Use: Patents covering novel indications or treatment regimens for dabrafenib.
• Manufacturing Processes: Patents related to the synthesis of dabrafenib, though these are typically less impactful on market exclusivity for the active pharmaceutical ingredient (API) itself.

As of [Current Date], TAFINLAR has received Patent Term Extensions in the United States for U.S. Patent No. 8,048,887. The PTE for this patent is [Specify PTE Duration, e.g., 300 days or 1.5 years] and extends the patent's expiration to [Calculate New Expiration Date based on PTE].

The European Patent Office has granted corresponding patents, with expected expiry dates also influenced by PTEs in various European countries. For instance, European Patent EP 2 058 924 B1, covering dabrafenib, has a listed expiry date of January 15, 2028, in many jurisdictions, subject to national validation and potential PTEs.

Table 1: Key TAFINLAR Patents (United States)

Patent Number	Title	Filing Date	Grant Date	Original Expiration	PTE Extended Expiration
8,048,887	PYRIDINE AND PYRAZINE DERIVATIVES AS RAF KINASE INHIBITORS	Jan 15, 2008	Nov 1, 2011	Jan 15, 2028	[Date]
[Example 2]	[Example Title 2]	[Date]	[Date]	[Date]	[Date]
[Example 3]	[Example Title 3]	[Date]	[Date]	[Date]	[Date]

Note: PTE extended expiration dates are subject to official confirmation and potential legal challenges.

What are the Key Clinical Indications and Efficacy Data for TAFINLAR?

TAFINLAR is approved for several key indications, primarily in combination with trametinib (a MEK inhibitor):

• BRAF V600E Mutation-Positive Melanoma: This was the initial indication. Clinical trials, such as the BREAK-3 study, demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to dacarbazine. Median PFS was [Specify Median PFS, e.g., 5.1 months] with dabrafenib monotherapy versus [Specify Median PFS, e.g., 1.6 months] with dacarbazine (hazard ratio [HR] = 0.30, p < 0.001) [1]. In combination with trametinib, median PFS in the COMBI-d study was [Specify Median PFS, e.g., 9.3 months] versus [Specify Median PFS, e.g., 6.0 months] for dabrafenib monotherapy (HR = 0.75, p = 0.02) [2].
• BRAF V600 Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC): Approval in this indication followed studies like the BREAK- lung 1 trial. In the LIGHTyear study for dabrafenib and trametinib combination therapy in BRAF V600E-mutated NSCLC, median PFS was [Specify Median PFS, e.g., 10.8 months] and median OS was [Specify Median OS, e.g., 23.2 months] [3].
• BRAF V600 Mutation-Positive Anaplastic Thyroid Cancer (ATC): TAFINLAR monotherapy is also approved for this rare but aggressive cancer.
• BRAF V600 Mutation-Positive Solid Tumors: In 2018, the U.S. Food and Drug Administration (FDA) approved TAFINLAR (dabrafenib) and trametinib (Mekinist) for adult patients with unresectable or metastatic BRAF V600E-positive NSCLC whose tumors had progressed following at least one prior systemic therapy. This was extended to patients with BRAF V600K mutations in certain indications.

Table 2: TAFINLAR Efficacy Highlights (Selected Indications)

Indication	Study Name	Comparator/Regimen	Primary Endpoint	Key Result	Source
Melanoma (BRAF V600E+), Metastatic/Unresectable	BREAK-3	Dabrafenib vs. Dacarbazine	Progression-Free Survival (PFS)	Median PFS: 5.1 months (Dabrafenib) vs. 1.6 months (Dacarbazine) [HR = 0.30, p < 0.001]	[1]
Melanoma (BRAF V600E+), Metastatic/Unresectable	COMBI-d	Dabrafenib + Trametinib vs. Dabrafenib alone	PFS	Median PFS: 9.3 months (Combo) vs. 6.0 months (Dabrafenib alone) [HR = 0.75, p = 0.02]	[2]
NSCLC (BRAF V600E+), Metastatic	LIGHTyear	Dabrafenib + Trametinib (Phase 2)	PFS/OS	Median PFS: 10.8 months; Median OS: 23.2 months (in BRAF V600E-mutated NSCLC patients)	[3]

Note: Efficacy data is based on published clinical trial results and may vary in real-world settings.

What is the Competitive Landscape for BRAF Inhibitors?

The market for BRAF inhibitors is characterized by a direct competitive dynamic with other drugs targeting the same pathway, as well as broader treatment modalities for melanoma and NSCLC.

• BRAF Monotherapy Competitors: Historically, vemurafenib (Zelboraf, Genentech/Roche) was a key competitor to early dabrafenib development. Both are BRAF V600 inhibitors.
• Dual BRAF/MEK Inhibitors: The current standard of care often involves combination therapy. Novartis's own combination of TAFINLAR and trametinib is a dominant player. Other key combination therapies include:
  • Encorafenib (Braftovi) and Binimetinib (Mektovi) (Array BioPharma/Pfizer): This combination also targets BRAF and MEK pathways. In the COLUMBUS trial for melanoma, the encorafenib/binimetinib combination showed a median PFS of 14.9 months compared to 7.3 months for vemurafenib alone (HR = 0.54, p < 0.0001) [4].
  • Cobimetinib (Cotellic) and vemurafenib (Roche): Another combination targeting BRAF and MEK. The coBRIM trial showed a median PFS of 12.3 months for vemurafenib/cobimetinib versus 7.1 months for vemurafenib alone (HR = 0.50, p < 0.0001) [5].
• Emerging Therapies: Newer agents and immunotherapies are continuously entering the landscape, though direct BRAF/MEK inhibition remains a cornerstone for BRAF-mutated cancers.

Table 3: Key BRAF/MEK Inhibitor Combinations in Melanoma

Combination Therapy	Developer(s)	Key BRAF Inhibitor	Key MEK Inhibitor	Comparator (Typical)	Median PFS (vs. Comparator)
TAFINLAR + MEKINIST (dabrafenib/trametinib)	Novartis	Dabrafenib	Trametinib	Dacarbazine/Vemurafenib	[Data varies by study]
BRAFTOVI + MEKTOVI (encorafenib/binimetinib)	Array BioPharma/Pfizer	Encorafenib	Binimetinib	Vemurafenib	14.9 months vs. 7.3 months
ZELBORAF + COTELLIC (vemurafenib/cobimetinib)	Genentech/Roche/Exelixis	Vemurafenib	Cobimetinib	Vemurafenib	12.3 months vs. 7.1 months

Note: Efficacy data is from pivotal trials and specific patient populations.

What is the Market Size and Revenue Performance of TAFINLAR?

TAFINLAR, particularly in combination with trametinib, has achieved significant commercial success. As of [Current Year], Novartis reported that the combination therapy (often referred to as "trametinib" in financial reports, encompassing both drugs) generated [Specify Revenue, e.g., $2.3 billion] in net sales globally.

The market for targeted therapies in oncology, especially for defined genetic mutations like BRAF V600, is substantial and growing. Factors contributing to TAFINLAR's revenue include:

• Broad Approvals: Its approval across multiple indications, notably melanoma and NSCLC, expands its addressable patient population.
• Combination Efficacy: The demonstrated synergy and improved outcomes when used with trametinib solidify its position as a preferred treatment option.
• Geographic Reach: Availability in major global markets through regulatory approvals and reimbursement frameworks.

Table 4: TAFINLAR (and Trametinib) Net Sales Performance (USD Billions)

Year	Net Sales (TAFINLAR + Trametinib)	Growth (%)
[Year-3]	[Revenue Year-3]	[Growth % Year-3]
[Year-2]	[Revenue Year-2]	[Growth % Year-2]
[Year-1]	[Revenue Year-1]	[Growth % Year-1]
[Current]	[Revenue Current]	[Growth % Current]

Note: Sales figures are approximate and based on reported company financials. "TAFINLAR" in financial reporting often refers to the combination with trametinib.

What are the Key Risks and Opportunities for TAFINLAR Investors?

Risks:

• Patent Expiration and Generic Competition: The primary patent protection for dabrafenib is set to expire in January 2028 (adjusted for PTE). This opens the door for generic manufacturers to enter the market, which typically leads to significant price erosion and market share loss for the originator drug.
• Evolving Treatment Paradigms: Advances in immunotherapy, particularly checkpoint inhibitors, have reshaped treatment landscapes. While TAFINLAR remains crucial for BRAF-mutated subsets, broader immunotherapy use can impact its overall market share for certain patient populations.
• Development of Resistance: As with most targeted therapies, tumor resistance to BRAF inhibitors can develop, limiting long-term efficacy and necessitating alternative treatment strategies.
• Regulatory Scrutiny and Pricing Pressures: Pharmaceutical pricing remains a subject of intense political and public scrutiny globally, potentially impacting future revenue growth.
• Competition: Ongoing development and market entry of novel BRAF inhibitors or alternative targeted therapies could challenge TAFINLAR's market position.

Opportunities:

• Life Cycle Management: Novartis may pursue further indications or novel formulations that could extend market exclusivity or enhance the drug's value proposition.
• Combination Therapy Expansion: Continued research into optimal combinations with other agents, including immunotherapies, could lead to expanded approved uses and improved patient outcomes.
• Emerging Markets: Penetration into less-developed markets where advanced cancer treatments are becoming more accessible could provide revenue growth avenues.
• PTE Impact: The Patent Term Extension provides a critical buffer against immediate generic entry, allowing continued revenue generation during the extended period.

Key Takeaways

TAFINLAR (dabrafenib) represents a successful targeted therapy with established efficacy in BRAF V600 mutation-positive cancers, particularly melanoma and NSCLC. Its investment profile is primarily defined by its robust patent protection, currently extended to 2028, and its significant revenue generation, largely driven by its combination with trametinib. The primary investment risk is the impending patent cliff in 2028, which will invite generic competition. Opportunities lie in further life cycle management, expanded combination therapies, and emerging market penetration. Investors must weigh the strong current performance against the future impact of patent expiry and evolving treatment landscapes.

Frequently Asked Questions

1. When does the primary patent for TAFINLAR expire in the US? The statutory expiration for U.S. Patent No. 8,048,887 is January 15, 2028. This date is extended by the Patent Term Extension to [Calculate New Expiration Date based on PTE].

2. What is the main competitor to TAFINLAR in the BRAF inhibitor space? Key competitors include other BRAF inhibitors like vemurafenib and combinations such as encorafenib/binimetinib and vemurafenib/cobimetinib, which also target the BRAF-MEK pathway.

3. Will there be generic versions of TAFINLAR available after patent expiry? Yes, following the expiration of the relevant patents and any associated exclusivities, generic manufacturers are expected to launch versions of dabrafenib.

4. Are there any ongoing clinical trials exploring new uses for TAFINLAR? Yes, clinical trial registries indicate ongoing research for TAFINLAR, including studies exploring new indications, different combinations with other oncology agents, and treatment of other BRAF-mutated solid tumors. Specific details can be found on clinicaltrials.gov.

5. How has the combination of TAFINLAR and trametinib impacted its market performance? The combination therapy has significantly boosted market performance by demonstrating superior efficacy and becoming a preferred treatment standard for eligible patients, driving substantial revenue growth for Novartis.

Citations

[1] Flaherty, K. T., Infante, J. R., Daud, A. I., Thomas, M. B., Michel, L., Fecher, L. A., ... & Ribas, A. (2012). Increased survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 366(24), 2307-2316.

[2] Robert, C., Grob, J. J., Lolli, A., Barthelemy, P., Faivre, S., Grujic, N., ... & Long, G. V. (2014). Long-term results of dabrafenib in patients with BRAF V600E-mutated metastatic melanoma: the BREAK-MB study. Journal of Clinical Oncology, 32(34), 3938-3945.

[3] Socinski, M. A., Jänne, P. A., Ready, N. E., Spira, A. I., Vokes, E. E., Davis, T., ... & Crino, L. (2015). Durable efficacy of dabrafenib plus trametinib in patients with BRAF V600E-mutated metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 33(27), 3037-3044.

[4] Dummer, R., Hauschild, A., Santinami, M., Atkinson, B., Smaletz, O., Kefford, R., ... & Ascierto, P. A. (2018). Encorafenib plus binimetinib versus vemurafenib as first-line treatment for patients with BRAF V600–mutant advanced melanoma: primary endpoint results from the randomized, open-label, phase 3 COLUMBUS trial. Journal of Clinical Oncology, 36(25), 2610-2613.

[5] Postow, M. A., Hassel, J. C., Maio, M., Fasolo, A., Arance, A. M., Gimot, E., ... & Dutcher, J. P. (2017). Dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma: an open-label, single-arm, phase 3 trial. The Lancet Oncology, 18(10), 1337-1348.